Serum (1→3)-β-d-glucan measurement as an early indicator of Pneumocystis jirovecii pneumonia and evaluation of its prognostic value

Clinical Microbiology and Infection

Volumn 17, Issue 4, 2011, Pages 595-602

  Held, J ^a   Koch, M S ^a   Reischl, U ^b   Danner, T ^a   Serr, A ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Pneumocystis jirovecii pneumonia; Prognosis; d Glucan

Indexed keywords

BETA GLUCAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOCOMPROMISED PATIENT; LUNG LAVAGE; MALE; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

FUNGI; PNEUMOCYSTIS JIROVECII;

EID: 79952716303     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2010.03318.x     Document Type: Article

References (25)

1. Ponce CA, Gallo M, Bustamante R, Vargas SL. Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clin Infect Dis 2010; 50: 347-353.
2. Morris A, Wei K, Afshar K, Huang L. Epidemiology and clinical significance of pneumocystis colonization. J Infect Dis 2008; 197: 10-17.
3. Desmet S, Van Wijngaerden E, Maertens J et al. Serum (1-3)-beta-d-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol 2009; 47: 3871-3874.
4. Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, Sulahian A. Contribution of the (1→3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2008; 46: 1009-1013.
5. Shimizu A, Oka H, Matsuda T, Ozaki S. (1→3)-beta-D glucan is a diagnostic and negative prognostic marker for Pneumocystis carinii pneumonia in patients with connective tissue disease. Clin Exp Rheumatol 2005; 23: 678-680.
6. Iikuni N, Kitahama M, Ohta S, Okamoto H, Kamatani N, Nishinarita M. Evaluation of Pneumocystis pneumonia infection risk factors in patients with connective tissue disease. Mod Rheumatol 2006; 16: 282-288.
7. Nakamura H, Tateyama M, Tasato D et al. Clinical utility of serum beta-D-glucan and KL-6 levels in Pneumocystis jirovecii pneumonia. Intern Med 2009; 48: 195-202.
8. Watanabe T, Yasuoka A, Tanuma J et al. Serum (1→3) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis 2009; 49: 1128-1131.
9. Yasuoka A, Tachikawa N, Shimada K, Kimura S, Oka S. (1→3) beta-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin Diagn Lab Immunol 1996; 3: 197-199.
10. Obayashi T, Yoshida M, Mori T et al. Plasma (1→3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995; 345: 17-20.
11. Probst M, Ries H, Schmidt-Wieland T, Serr A. Detection of Pneumocystis carinii DNA in patients with chronic lung diseases. Eur J Clin Microbiol Infect Dis 2000; 19: 644-645.
12. Larsen HH, Masur H, Kovacs JA et al. Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing Pneumocystis carinii pneumonia. J Clin Microbiol 2002; 40: 490-494.
13. Ikemura K, Ikegami K, Shimazu T, Yoshioka T, Sugimoto T. False-positive result in Limulus test caused by Limulus amebocyte lysate-reactive material in immunoglobulin products. J Clin Microbiol 1989; 27: 1965-1968.
14. Kanda H, Kubo K, Hamasaki K et al. Influence of various hemodialysis membranes on the plasma (1→3)-β-D-glucan level. Kidney Int 2001; 60: 319-323.
15. Kato A, Takita T, Furuhashi M, Takahashi T, Maruyama Y, Hishida A. Elevation of blood (1→3)-beta-D-glucan concentrations in hemodialysis patients. Nephron 2001; 89: 15-19.
16. Ogawa M, Hori H, Niiguchi S, Azuma E, Komada Y. False positive plasma (1→3)-β-D-glucan following immunoglobulin product replacement in adult bone marrow recipient. Int J Hematol 2004; 80: 97-98.
17. Usami M, Ohata A, Horiuchi T, Nagasawa K, Wakabayashi T, Tanaka S. Positive (1→3)-beta-D-glucan in blood components and release of (1→3)-beta-D-glucan from depth-type membrane filters for blood processing. Transfusion 2002; 42: 1189-1195.
18. Ohata A, Usami M, Horiuchi T, Nagasawa K, Kinoshita K. Release of (1→3)-beta-D-glucan from depth-type membrane filters and their in vitro effects on proinflammatory cytokine production. Artif Organs 2003; 27: 728-735.
19. Fujii T, Nakamura T, Iwamoto A. Pneumocystis pneumonia in patients with HIV infection: clinical manifestations, laboratory findings, and radiological features. J Infect Chemother 2007; 13: 1-7.
20. Cuétara MS, Alhambra A, Chaves F, Moragues MD, Pontón J, del Palacio A. Use of a serum (1→3)-beta-D-glucan assay for diagnosis and follow-up of Pneumocystis jiroveci pneumonia. Clin Infect Dis 2008; 47: 1364-1366.
21. Yoshida M, Roth RI, Grunfeld C, Feingold KR, Levin J. Soluble (1→3)-beta-D-glucan purified from Candida albicans: biologic effects and distribution in blood and organs in rabbits. J Lab Clin Med 1996; 128: 103-114.
22. Del Bono V, Mularoni A, Furfaro E et al. Clinical evaluation of a (1→3)-beta-D-glucan assay for presumptive diagnosis of Pneumocystis jiroveci pneumonia in immunocompromised patients. Clin Vaccine Immunol 2009; 16: 1524-1526.
23. Marty FM, Koo S, Bryar J, Baden LR. (1→3)-beta-D-glucan assay positivity in patients with Pneumocystis (carinii) jiroveci pneumonia. Ann Intern Med 2007; 147: 70-72.
24. Tasaka S, Hasegawa N, Kobayashi S et al. Serum indicators for the diagnosis of pneumocystis pneumonia. Chest 2007; 131: 1173-1180.
25. Mennink-Kersten MA, Ruegebrink D, Verweij PE. Pseudomonas aeruginosa as a cause of 1, 3-beta-D-glucan assay reactivity. Clin Infect Dis 2008; 46: 1930-1931.